Mammalian & Microbial Manufacturing in Europe
Our AGC Biologics Copenhagen site is one of the largest and most active facilities in our global network. The core teams of scientists have 30+ years of expertise in development and manufacturing, including eight commercial products brought to market. This means your product is being managed by some of the best in the business.
Got a project? Let's talk.
Get all the details on this site.
Our in-depth fact sheet provides all the details you need on the complete capabilities and services of this campus and its abilities to support your next project.
DOWNLOAD NOWMammalian Manufacturing
Our mammalian manufacturing offers single-use bioreactors from 500 L to 2,000 L, with scales up to 12,000 L via modular multi-pack capabilities. Additionally, our multiple independent mammalian lines utilize fed-batch and perfusion manufacturing processes.
Microbial Fermentation Manufacturing
Our microbial manufacturing features up to 1,500 L working volume using stainless steel Microbial fermenters and 2,200 L vessel volume, with extensive cGMP manufacturing experience, from E. coli to yeasts.
Global Overview
Process Development
Full development service from lab development to commercial production including process transfer, cell line development, upstream and downstream development, process characterization and validation, and more.
New Expansion
The new Copenhagen site expansion, features 18,000 m2 distributed across manufacturing, quality control laboratories and technical and warehouse areas. In addition, 8 x 2,000 L single-use bioreactor production lines, 1 x 500 L perfusion bioreactor, two downstream purification lines, and more.
Our Copenhagen campus has achieved a Silver EcoVadis Sustainability Rating and has achieved many certifications, including:
AGC Biologics Copenhagen has published ESG figures in response to evolving regulations and growing customer demand for transparency. This report provides a more comprehensive view of our sustainability performance, following a CSRD-compliant structure and including key disclosure requirements. It marks an important first step in our commitment to sustainable practices and transparent reporting.
